

Application No. 10/612,731

2

Docket No. 57222(71699)

RECEIVED  
CENTRAL FAX CENTERAMENDMENTS TO THE CLAIMS

MAR 01 2010

Claim 1. (Currently Amended) A method of qualifying the prostate cancer status in a subject comprising:

(a) measuring the amount of at least one biomarker in a sample from the subject, wherein the biomarker is selected from the group consisting of

Marker I: having a molecular weight of about 7.808 kD in a biological sample from the subject,

Marker II: having a molecular weight of about 14.576 kD

Marker III: having a molecular weight of about 2.062 kD

Marker IV: having a molecular weight of about 7.974 kD

Marker V: having a molecular weight of about 6.677 kD

Marker VI: having a molecular weight of about 3.936 kD

Marker VII: having a molecular weight of about 60.958 kD

Marker VIII: having a molecular weight of about 5.149 kD

Marker IX: having a molecular weight of about 5.861 kD

Marker X: having a molecular weight of about 28.098 kD

Marker XI: having a molecular weight of about 2.996 kD

Marker XII: having a molecular weight of about 24.346 kD

Marker XIII: having a molecular weight of about 6.722 kD

Marker XIV: having a molecular weight of about 5.999 kD

Marker XV: having a molecular weight of about 6.158 kD

Marker XVI: having a molecular weight of about 55.785 kD

Marker XVII: having a molecular weight of about 2.540 kD

Marker XVIII: having a molecular weight of about 8.019 kD

Marker XIX: having a molecular weight of about 4.658 kD

Marker XX: having a molecular weight of about 14.703 kD

Marker XVI: having a molecular weight of about 2.68 kD

Marker XXII: having a molecular weight of about 3.16 kD

Marker XXIII: having a molecular weight of about 10.3 kD

Marker XXIV: having a molecular weight of about 10.8 kD

BOS2 739630.1

Application No. 10/512,731

3

Docket No.: 57222(71699)

~~Marker XXV: having a molecular weight of about 12.7 kD~~~~Marker XXVI: having a molecular weight of about 17.9 kD~~~~Marker XXVII: having a molecular weight of about 2.79 kD~~~~Marker XXVIII: having a molecular weight of about 3.32 kD~~~~Marker XXIX: having a molecular weight of about 4.29 kD~~~~Marker XXX: having a molecular weight of about 15.9 kD~~~~Marker XXXI: having a molecular weight of about 16.1 kD~~~~Marker XXXII: having a molecular weight of about 16.3 kD, and combinations thereof, and~~

(b) wherein a decrease in the amount of marker I as compared to a control correlating the measurement is correlated with prostate cancer status.

Claim 2. (original) The method of claim 1 further comprising:

(c) managing subject treatment based on the status.

Claim 3. (original) The method of claim 2, wherein managing subject treatment is selected from ordering more tests, performing surgery, and taking no further action.

Claim 4. (Currently Amended) The method of claim 2 further comprising:

(d) measuring the ~~at least one biomarker~~ after subject management.

Claims 5-10. (Cancelled)

Claim 11. (currently amended) The method of claim 1 ~~any of claims 1-10~~ wherein the marker is detected by mass spectrometry.

Claim 12. (currently amended) The method of claim 1 ~~any of claims 1-10~~ wherein the marker is detected by capturing the marker on a biochip having an affinity surface and detecting the captured marker by SELDI.

Claims 13-77. (cancelled)

BOS2 739630.1